Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present DanDrit Biotech USA, Inc. (OTC: DDRT).

Full DD Report for DDRT

You must become a subscriber to view this report.


Recent News from (OTC: DDRT)

Dandrit Biotech Announces Filing Of Listing Application To The Nasdaq Capital Market
LOS ANGELES , Feb. 26, 2018 /PRNewswire/ --  DanDrit Biotech USA , Inc. ("DanDrit") finalized its acquisition (the "Acquisition") of Enochian Biopharma Inc. ("Enochian") on February 16, 2018 . Enochian develops innovative proprietary technologies in HIV/AIDS. DanDrit believes that...
Source: PR Newswire
Date: February, 26 2018 11:11
DanDrit Biotech Announces Completion Of The Acquisition Of Enochian
LOS ANGELES , Feb. 19, 2018 /PRNewswire/ --  DanDrit Biotech USA , Inc. ("DanDrit") is pleased to announce the completion of its previously reported acquisition (the "Acquisition") of Enochian Biopharma Inc. ("Enochian") on February 16, 2018 . As a result of the Acquisition, DanDr...
Source: PR Newswire
Date: February, 19 2018 18:48
DanDrit Signs Agreement to Acquire Enochian Biopharma Inc.
NEW YORK , Jan. 23, 2018 /PRNewswire/ --  DanDrit Biotech USA , Inc. ("DanDrit") signed an agreement to acquire Enochian Biopharma Inc. ("Enochian"). Enochian is developing an innovative proprietary technology in the field of HIV/AIDS. DanDrit believes that through the acquisition,...
Source: PR Newswire
Date: January, 23 2018 14:51
DanDrit Announces New Scientific Advisory Board Members
NEW YORK , Jan. 23, 2018 /PRNewswire/ -- DanDrit Biotech USA , Inc. ("DanDrit") announces the appointment of Ambassador Mark Dybul , MD, as Chairman, and Steven Deeks , MD to its Scientific Advisory Board. "We are excited about the addition of two renowned experts on the treatment...
Source: PR Newswire
Date: January, 23 2018 14:44
Daily OTC Markets Round-Up - 9/19/2017
This article is part of an ongoing series which provides information relevant to stocks on the OTC markets on a daily basis. It provides stocks with the most daily volume, and the biggest winners/losers in terms of changes in stock price. It then provides information on the stocks which have e...
Source: SeekingAlpha
Date: September, 20 2017 13:23
Daily OTC Markets Round-Up - 9/18/2017
This article is part of an ongoing series which provides information relevant to stocks on the OTC markets on a daily basis. It provides stocks with the most daily volume, and the biggest winners/losers in terms of changes in stock price. It then provides information on the stocks which have e...
Source: SeekingAlpha
Date: September, 19 2017 14:16
DanDrit Biotech Announces New Therapeutic Research Strategy
NEW YORK , June 14, 2017 /PRNewswire/ -- DanDrit Biotech USA , Inc. ("DanDrit" or the "Company") (OTCQB: DDRT) is pleased to announce that on June 6, 2017 , Mr. Rene Sindlev and Mr. Torben Bjørn Christensen, joined DanDrit's Board of Directors (the "Board") as part of a new str...
Source: PR Newswire
Date: June, 14 2017 09:00
Blake Insomnia Therapeutics Inc. Announces Appointment of Dr. Eric Leire to its Board of Directors
NEW YORK, May 09, 2017 (GLOBE NEWSWIRE) -- Blake Insomnia Therapeutics Inc. (OTCQB:BKIT) a New York based pharmaceutical company is pleased to announce the appointment of Dr. Eric Leire to join CEO Birger Jan Olsen on its Board of Directors. Dr. Leire has currently been the CEO of DanDri...
Source: GlobeNewswire
Date: May, 09 2017 13:20
DanDrit Biotech USA Inc. Announces The Purchase Of OncoSynergy, Inc.
NEW YORK , April 5, 2016 /PRNewswire/ -- DanDrit Biotech USA Inc. (OTCQB: DDRT) today announced that it has entered into an agreement to acquire privately-held OncoSynergy, Inc. Based in San Francisco , OncoSynergy develops novel oncology drug candidates including the first-in-class ...
Source: PR Newswire
Date: April, 05 2016 09:45

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-03-196.006.056.056.0030,875
2018-03-186.006.056.056.0030,875
2018-03-176.006.056.056.0030,875
2018-03-166.006.056.056.0030,875
2018-03-155.306.006.005.3011,600

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-03-169,90930,87532.0939Cover
2018-03-154,70011,60040.5172Short
2018-03-1414,42023,64860.9777Short
2018-03-123,0204,22071.5640Short
2018-03-0913,66020,06068.0957Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on DDRT.


About DanDrit Biotech USA, Inc. (OTC: DDRT)

Logo for DanDrit Biotech USA, Inc. (OTC: DDRT)

We are a US based clinical stage company developing new approaches to leverage the immune system to fight cancers and infectious diseases. Our vision is to radically improve outcomes for patients with unmet needs in HIV/AIDS and oncology. Our intent is to develop transformative, multi indication, platform drugs that harness the power of immunotherapy and change the standards of care of AIDS and cancer. We will expedite programs to market through strategic development and leveraging enhanced FDA programs and corporate partnerships.

 

Contact Information

 

 

Current Management

  • Eric Leire / CEO
    • MD, MBA
  • Robert E. Wolfe / CFO
  • Evelyn D An / Independent Director
  • Mark R. Dybul /
  • Henrik GronfeldtSorensen /
  • Eric Leire / MD, MBA
  • Carl Sandler /
  • James Sapirstein / Independent Director
  • Rene Sindlev /
  • Robert E. Wolfe /

Current Share Structure

  • Market Cap: $93,898,535 - 03/09/2018
  • Authorized: 100,000,000 - 09/28/2017
  • Issue and Outstanding: 13,910,894 - 02/07/2018
  • Float: 7,402,528 - 09/28/2017

 


Recent Filings from (OTC: DDRT)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 06 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 23 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: February, 09 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: January, 18 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: January, 17 2018
OTCQB Certification - OTCQB Certification
Filing Type: OTCQB Certification - OTCQB CertificationFiling Source: OTC Markets
Filing Date: January, 02 2018
Amendment to a previously filed 10-K
Filing Type: 10-K/AFiling Source: edgar
Filing Date: November, 20 2017
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: November, 20 2017
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: November, 17 2017
Notification that form 10-Q will be submitted late
Filing Type: NT 10-QFiling Source: edgar
Filing Date: November, 15 2017

 

 


Daily Technical Chart for (OTC: DDRT)

Daily Technical Chart for (OTC: DDRT)


Stay tuned for daily updates and more on (OTC: DDRT)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: DDRT)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in DDRT is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of DDRT and does not buy, sell, or trade any shares of DDRT. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/